MRSH — the #1 global broker at a 19% P/E discount

Marsh & McLennan Companies (NYSE: MRSH — ticker changed from MMC on January 14, 2026) qualifies on all three screens: ROE has held above 26% every year for five years, free cash flow reached $5.0 billion in FY2025 and $4.9 billion TTM, and the trailing P/E of 20.76× is 19.5% below the company's own five-year average of 25.78×. The stock is down 24% over the last 52 weeks and sitting 6% above its 52-week low. This is the 41st pick in the channel, and the first from Financial Services / Insurance Brokerage. 1

Three gates, all cleared:

ROE methodology note: StockAnalysis uses average common equity as the denominator (FY2023 32.89%, FY2024 31.79%, FY2025 29.35%, TTM 26.61%). SEC EDGAR XBRL period-end figures using total equity including non-controlling interests give FY2023 30.36%, FY2024 30.00%, FY2025 27.16%. Both methods confirm all three years clear 15% by a wide margin. Fiscal year = calendar year for MMC/MRSH. 2 3

Marsh & McLennan has been placing insurance for businesses since 1871. Today it is the largest insurance broker in the world by revenue, running four distinct operating segments that collectively generated $26.98 billion in revenue in FY2025. 4

Marsh (~50% of total revenue) is the core brokerage engine. It arranges property, casualty, marine, aviation, and specialty insurance for multinational corporations, mid-market companies, and government entities across 130+ countries. When a pharmaceutical company needs product liability coverage in 40 jurisdictions, or when a renewable energy developer wants to insure an offshore wind farm, Marsh is the firm placing that risk into the insurance market. As the #1 global broker by revenue — $25.33 billion in brokerage revenues (2024, Insurance Information Institute) — Marsh brings placement power that smaller peers cannot match: carriers grant Marsh delegated underwriting authority and prioritize its submissions. 5

Guy Carpenter (~9% of revenue) is the #2 global reinsurance broker, with $2.36 billion in revenues. Reinsurance is the insurance that insurance companies buy to offload their own catastrophe risk. It is a high-stakes, technically demanding market where relationships, data modeling, and analytical depth determine which broker gets the business — and Guy Carpenter has built all three over 130 years. 5

Mercer (~25% of revenue) is one of the world's three largest HR and benefits consulting firms. It advises corporations on employee benefits design, retirement plans, workforce analytics, and executive compensation. Mercer manages approximately $692 billion in assets under advisement (AUA) for pension and investment clients. This segment is economically distinct from insurance brokerage — revenue is fee-based and driven by headcount and M&A advisory cycles rather than insurance premium volumes.

Oliver Wyman (~16% of revenue) is a top-7 global management consulting firm. It serves financial services, healthcare, transportation, and industrial clients on strategy, risk, and operations. The acquisition of CR3 Partners (announced May 2026) adds restructuring and turnaround advisory capability.

How insurance brokerage actually generates profit is different from most businesses on this channel. The broker earns a commission — typically 10–15% of premiums placed — from the insurer, not the client. Revenue moves with premium volumes across the market, which means hard insurance markets (rising premiums) directly expand brokerage revenue without the broker taking any insurance risk on its own balance sheet. This asset-light model is the structural reason why MMC has generated 30%+ ROE while holding $21–22 billion in debt: the capital structure resembles a professional services firm, not an insurance company.

All data points from StockAnalysis using average common equity as denominator. 2

Period-end ROE sourced from SEC EDGAR XBRL (total equity including non-controlling interests). The 2–3 percentage-point gap between the two methods reflects the difference between average vs. closing equity base and the inclusion of non-controlling interests. 3

The TTM ROE of 26.61% is the lowest reading in five years. Two things are driving that: net income slipped to $3.93B TTM from $4.16B in FY2025 as margin compressed (TTM operating margin 21.70% vs. 23.78% at FY2024 peak), and the equity base expanded modestly from the McGriff acquisition goodwill. The trend is worth monitoring, but even at 26.6% the ROE is roughly 3.5× the current peer median of 7.20% (see peer table below) — a comparison complicated by distorted peer ROE metrics, which the peer section addresses directly. 4

ROIC — which uses total invested capital as the denominator rather than equity, and is therefore not distorted by leverage — stands at 14.60% TTM, approximately 27% above the peer median ROIC of 11.49%. ROIC above WACC (generally estimated at 8–9% for large-cap financial services) is the signature of a business with durable competitive returns. 1

FCF = operating cash flow minus capital expenditures. CapEx has declined from $470M in FY2022 to $291M in FY2025 (low capital intensity of professional services confirmed). 6

The FY2025 FCF jump of 25.5% — from $3.99B to $5.00B — was driven by a 23% increase in operating cash flow with CapEx continuing to fall. FCF/Net Income was approximately 120%, meaning the business converts earnings to cash at better than 1-for-1. That ratio matters: it means the income statement is not flattering the cash generation; cash generation is actually flattering the income statement.

TTM FCF of $4.93B is marginally lower than FY2025's $5.00B, primarily because Q1 2026 working capital consumed some cash as the quarter ended. At the current $80.17B market cap, the FCF yield is 6.15% — earned against a business with investment-grade credit ratings and consistent cash generation for 20+ consecutive years. 1

Share buybacks consumed $2.16B in FY2025 and $2.60B TTM — roughly 50% of FCF in each period. The dividend is $3.60 per share annually, with 16 consecutive years of increases and a payout ratio of 45.04% of TTM EPS. The combination of a 6.15% FCF yield, a 45% payout ratio, and an investment-grade balance sheet means the dividend has substantial coverage headroom. 6 1

Historical P/E context: As of June 24, 2026, trailing P/E is 20.76×, forward P/E 15.58×, and FCF yield 6.15%. 1 MRSH's annual P/E over the last five fiscal years: FY2021 28.36×, FY2022 27.40×, FY2023 25.16×, FY2024 25.97×, FY2025 22.01× — 5-year average 25.78×. The current trailing P/E of 20.76× is 19.5% below that average. This is not a company that has historically been cheap. Over the same five years, earnings grew from $6.13 diluted EPS (FY2021) to $8.43 (FY2025) — the multiple compression is entirely a re-rating of the same growing earnings stream. 2

Peer comparison (insurance brokerage, as of June 24, 2026):

Sources: 7 8 9 10 11

A few flags on that table. AJG's P/E of 35.71× is not a valuation endorsement — it reflects that AJG's reported ROE is 7.01% (depressed by a $23.80B equity base inflated from 300+ acquisitions, including the pending $13.45B AssuredPartners deal), with forward P/E of 16.19× suggesting earnings will normalize as M&A goodwill amortizes. RYAN at 45.54× P/E reflects a 2021-IPO growth premium, D/E of 3.07×, and a net profit margin of only 3.50%. AON's ROE of 46.45% looks exceptional but is amplified by thin book value ($9.98B equity supporting $3.94B in annual net income) — ROIC of 16.52% is the cleaner measure and puts AON just slightly ahead of MRSH at 14.60%. The ROIC comparison is the fairest apples-to-apples look across a peer group where capital structures and acquisition accounting diverge sharply. 7 9 11

The P/B premium (MRSH at 5.49× vs. peer median 3.09×) partly reflects MRSH's negative tangible book value (−$29.13 per share TTM) from $24.27B in accumulated goodwill across decades of acquisitions. On an EV/EBITDA basis — which strips goodwill accounting distortions — MRSH trades at a 7.6% discount to peer median. 12

All figures from StockAnalysis income statement. 4

Revenue has compounded at roughly 6.4% annually over five years. The FY2025 revenue acceleration to 10.3% was driven partly by the McGriff Insurance Services acquisition, which closed in September 2024 for $7.75 billion. That acquisition also contributed to the D/E ratio rising from 1.14 in FY2021 to 1.52 TTM — most of that debt was issued in FY2024 ($8.17B in long-term debt added). 4

The TTM margin compression — operating margin down to 21.70% from the FY2024 peak of 23.78%, net margin at 14.57% — is the most significant earnings development in the current data window. Q1 2026 EPS came in at $2.37, down from $2.81 in Q1 2025. MRSH reported this as its 19th consecutive year of margin expansion (on an underlying adjusted basis), but the GAAP TTM figures show the compression. The gap between adjusted and GAAP trends is worth monitoring in Q2 2026 results.

Sources: 12 1

The D/E of 1.52× is elevated but carries three investment-grade credit ratings that have been affirmed or reaffirmed in the past 18 months: S&P A− (Stable, affirmed November 2025), Moody's A3 (Stable, affirmed September 2024), and Fitch A− (Stable, affirmed September 2025, reaffirmed February 2026). 13 14 15

Interest coverage at 7.04× is the weakest point on the balance sheet. It is comfortably above distress territory, but lower than the 9–10× coverage ratios most large-cap investment-grade companies maintain. This is the leverage taken on to fund McGriff, and it will take several years of FCF to pay down meaningfully. For context, at $4.9B in TTM FCF and assuming roughly $600–700M in annual CapEx and dividends, MRSH has approximately $3.5–4.0B in annual net capacity for debt reduction — suggesting net debt could return to pre-McGriff levels within 5–6 years at current trajectory.

The negative tangible book value (−$29.13 per share) is a product of acquisition accounting, not operating losses. It does not affect the company's cash-generating capability or credit standing, but it does make book-value-based metrics (P/B, tangible equity) largely uninformative for MMC's valuation analysis.

Morningstar rates MRSH as a Narrow Moat company — not Wide. That assessment is fair, but the moat is durable. Five structural advantages underpin it. 16

Scale and placement power. MRSH places several hundred billion dollars in premiums annually. Carriers view Marsh submissions as pre-vetted and grant delegated underwriting authority. With $27.52B in TTM revenue versus AON's $17.49B and AJG's $14.20B, MRSH's volume advantage creates pricing leverage that smaller brokers cannot replicate. The top three brokers (MRSH + AON + AJG) collectively control approximately 52% of the top-five players' market share, per MarshBerry's 2025 Top 100 report. The DOJ's 2021 complaint blocking the AON-WTW merger identified Marsh as "the only other competitor with substantial share" in the market that AON and WTW combined would have dominated — a de facto acknowledgment of the oligopoly structure. 17

Switching costs. For a multinational corporation, switching insurance brokers means transferring dozens of complex, multi-jurisdictional policies — an operationally intensive process that creates genuine inertia. Large-account retention rates are cited above 95% in multiple independent analyses. 18

Data and analytics. MRSH ingests data from millions of policies and claims annually across every industry and geography. This proprietary dataset is operationalized through Marsh McLennan Unity, an AI-driven platform for risk benchmarking, predictive analytics, and real-time pricing intelligence. In April 2026, Marsh launched Risk Companion, an AI-powered analytics suite for risk managers. Annual investment in data and technology exceeds $300 million.

Multi-segment cross-selling. A Marsh risk client can also become a Mercer benefits client and an Oliver Wyman strategy client. The four business lines create a multi-threaded client relationship that competitors with single-segment models cannot match.

Brand and longevity. 'Marsh,' 'Guy Carpenter,' 'Mercer,' and 'Oliver Wyman' are individually recognized in their respective markets after 100+ years of operation in each case. C-suite trust at the level MMC operates — advising on billion-dollar risk decisions — takes decades to build and cannot be fast-tracked.

The FY2024 McGriff acquisition added $7.75B to the balance sheet and pushed D/E from ~1.14 to 1.52×. Interest coverage of 7.04× is adequate but not ample. If refinancing conditions deteriorate or if a soft insurance market compresses revenue, coverage could tighten toward 5–6×, which would draw credit rating scrutiny. The $22.45B debt load is not a crisis, but it constrains the balance sheet for the next 3–5 years. 12

On February 9, 2026, OpenAI approved the first AI insurance application, triggering a sector-wide sell-off in insurance broker stocks. Barron's flagged the structural concern in March 2026: AI agents with access to carrier pricing data could theoretically replace the broker's advisory and placement function for simpler commercial lines. MRSH's CEO John Doyle addressed geopolitical and climate risks at Davos in January 2026 but did not directly rebut the AI concern publicly. The risk is asymmetric: standardized SME commercial insurance is more vulnerable than the complex multinational risk placements that generate MRSH's highest-margin revenues. Marsh has proactively responded with Risk Companion (AI-driven risk suite) and ongoing platform investment, positioning the technology as augmentative rather than disintermediating. 19

CEO John Q. Doyle sold 16,656 shares (proceeds ~$2.69M) on June 2, 2026, and 16,655 shares (proceeds ~$3.05M) on March 4, 2026 — both exercise-and-sell transactions at current market prices. CMO John Jude Jones sold 2,362 shares (~$410K) on March 11, 2026; Oliver Wyman Group CEO Nick Studer sold 3,837 shares (~$706K) on March 3, 2026. Total insider ownership is 0.10–0.20% of shares outstanding; institutional ownership is 95.48%. Net insider transaction is −3.94%. There are no disclosed open-market purchases in 2025–2026. Routine option exercise-and-sell is not inherently bearish, but the absence of any open-market buying at a 24% price decline is a data point. 19

MRSH's TTM operating margin of 21.70% is the lowest since FY2022. Insurance brokerage revenue moves with premium volumes — a soft pricing cycle (carriers cutting rates to gain market share, common in years with benign catastrophe losses) compresses MRSH's top line without equivalent cost reductions. The company has delivered 19 consecutive years of margin expansion on an underlying adjusted basis, but the GAAP TTM picture is deteriorating. William Blair analyst Adam Klauber has maintained a Hold rating with the characterization: "Solid near-term execution but pricing headwinds limit upside." 20

Marsh McLennan Agency (MMA) filed suit on June 9, 2026 against Patriot Growth Insurance Services and eight former employees, alleging the poaching of 11 surety bond team members. This is a business-continuity matter rather than a systemic legal risk. A separate $20M errors-and-omissions suit from Old Ironsides Energy reportedly collapsed in 2025. The 2005 Spitzer bid-rigging settlement ($850M) is fully resolved with no ongoing legacy actions detected. No DOJ, SEC, or federal regulatory investigations are currently active. 21

Short interest increased from 5.86M shares to 7.32M shares in the most recent reporting period — a 24.9% jump month-over-month, bringing the float short to 1.52%. Days to cover is 2.57. At this level the short position is not a pressure signal for an $80B company (days to cover is very low), but the directional increase in betting against the stock is worth noting alongside the insider selling pattern. 1

Q2 2026 earnings — July 21, 2026, before market open. This is the most important near-term data point. Investors will watch for underlying revenue growth in Risk & Insurance Services (any signs of pricing cycle softening), whether the McGriff integration is contributing as modeled, and Q2 margin trajectory. The last earnings release (Q1 2026, April 16) showed revenue ahead of analyst expectations but EPS of $2.37 below consensus due to margin compression. 1

Dividend: $3.60/year, 16-year consecutive growth streak, 2.17% yield. Most recent ex-dividend date was April 9, 2026. The 5-year dividend CAGR is approximately 9.5%; the trailing 12-month growth was 10.43%. Payout ratio of 45.04% and FCF/dividend coverage of 13.7× give the streak significant durability. 1

Analyst consensus: Moderate Buy, average price target $199.88. Among 16 analysts with ratings in the last three months (TipRanks): 6 Buy, 9 Hold, 1 Sell. The average 12-month price target of $199.88 implies 20.4% upside from the $165.96 June 24 close. StockAnalysis reports 23 analysts at an average target of $199.57. Notable recent changes: Citigroup upgraded from Neutral to Buy ($200 PT) on May 6, 2026; Goldman Sachs upgraded from Sell to Neutral ($200 PT) on May 6, 2026; Bank of America Securities reiterated Sell with a $174 PT (down from $181) on April 14, 2026. 20

52-week range: $156.60 – $220.32. Current price of $165.96 is 5.98% above the 52-week low and 24.67% below the 52-week high. The stock has declined 24.26% over the past 52 weeks. Beta is 0.61 (5-year). Recent acquisitions completing integration: TriBridge Partners (closed June 1, 2026), CR3 Partners (announced May 2026), AltamarCAM private markets expansion (announced March 2026). Formula 1 partnership announced April 28, 2026 — Marsh named Official Risk Partner and Official Insurance Brokering Partner for the F1 series. 19